BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,037 filers reported holding BAXTER INTL INC in Q1 2015. The put-call ratio across all filers is 0.65 and the average weighting 0.4%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $270,445 | -15.6% | 7,166 | +1.9% | 0.02% | -22.7% |
| Q2 2023 | $320,515 | +25.4% | 7,035 | +11.7% | 0.02% | 0.0% |
| Q1 2023 | $255,528 | +79752.5% | 6,300 | +0.4% | 0.02% | -21.4% |
| Q4 2022 | $320 | -99.9% | 6,276 | +34.2% | 0.03% | +7.7% |
| Q3 2022 | $252,000 | -23.6% | 4,678 | -9.0% | 0.03% | -25.7% |
| Q2 2022 | $330,000 | +312.5% | 5,140 | +424.5% | 0.04% | +1650.0% |
| Q1 2019 | $80,000 | +247.8% | 980 | +180.0% | 0.00% | +100.0% |
| Q4 2018 | $23,000 | -91.1% | 350 | -95.5% | 0.00% | -95.0% |
| Q3 2015 | $258,000 | -53.0% | 7,853 | 0.0% | 0.02% | -51.2% |
| Q2 2015 | $549,000 | +2.0% | 7,853 | 0.0% | 0.04% | -2.4% |
| Q1 2015 | $538,000 | -6.4% | 7,853 | 0.0% | 0.04% | +10.5% |
| Q4 2014 | $575,000 | +1.8% | 7,853 | -0.3% | 0.04% | -2.6% |
| Q3 2014 | $565,000 | -9.3% | 7,878 | -8.6% | 0.04% | -7.1% |
| Q2 2014 | $623,000 | -1.6% | 8,615 | 0.0% | 0.04% | -2.3% |
| Q1 2014 | $633,000 | +5.7% | 8,615 | 0.0% | 0.04% | +4.9% |
| Q4 2013 | $599,000 | +5.5% | 8,615 | -0.3% | 0.04% | -8.9% |
| Q3 2013 | $568,000 | -9.4% | 8,640 | -4.5% | 0.04% | -8.2% |
| Q2 2013 | $627,000 | – | 9,050 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |